July 24, 2014 11:00 UTC

Compugen to Present Immune Checkpoint Related Research at Two Scientific Conferences

Utilization of predictive discovery to identify 11 novel checkpoint molecules to be presented at Immunotherapies and Vaccines Summit in Boston

Results for CGEN-15001 fusion protein based on checkpoint protein candidate to be presented at International Conference on Immune Tolerance in Amsterdam

TEL AVIV, Israel--(BUSINESS WIRE)-- Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two upcoming scientific conferences. On August 11, John Hunter, PhD, Site Head & Vice President, Antibody Research & Development at Compugen USA, Inc., will present at the Immunotherapies and Vaccines Summit (ImVacs) being held from August 11-14, in Boston, MA. In his talk, which is scheduled as part of the Immunomodulatory Therapeutic Antibodies for Cancer: Discovery and Development of the Next Wave of Checkpoint Inhibitors track, Dr. Hunter will discuss how Compugen has utilized its predictive discovery platforms to identify 11 novel immune checkpoints which potentially can serve as targets for antibody immunotherapy in cancer. Dr. Hunter will present validation data for two of these targets, CGEN-15049 and CGEN-15052.

The Company will also present at the 3rd International Conference on Immune Tolerance 2014, from September 28-30, 2014 in Amsterdam, The Netherlands. In a talk titled, CGEN-15001, a novel immune-modulatory Fc fusion protein is efficacious in models of autoimmune diseases and induces immune tolerance, Iris Hecht, PhD, Principal Scientist at Compugen, will review results for CGEN-15001, a fusion protein based on another immune checkpoint candidate discovered by the Company. Dr. Hecht will present results demonstrating long lasting efficacy in animal models of several autoimmune diseases as well as data supporting potential restoration of immune tolerance by CGEN-15001. Immune tolerance induction is a highly sought-after approach for treatment of autoimmune diseases such as rheumatoid arthritis, multiple sclerosis and type 1 diabetes.

Also at the Amsterdam conference, CGEN-15001 will be the subject of a poster presentation by Joseph R. Podojil, PhD, from the laboratory of Stephen Miller, Judy Gugenheim Research Professor of Microbiology-Immunology at Northwestern University Feinberg School of Medicine. In his presentation, titled Tolerogenic and immunomodulatory effects in the EAE model of multiple sclerosis induced by CGEN-15001, an Fc- fused protein derived from a novel immune checkpoint, Dr. Podojil will present data on the cellular mechanism underlying restoration of immune balance and induction of immune tolerance by CGEN-15001, suggesting that CGEN-15001 is a promising drug candidate for the treatment of autoimmune diseases.

About Compugen

Compugen is a leading drug discovery company focused on therapeutic proteins and monoclonal antibodies to address important unmet needs in the fields of immunology and oncology. The Company utilizes a broad and continuously growing integrated infrastructure of proprietary scientific understandings and predictive platforms, algorithms, machine learning systems and other computational biology capabilities for the in silico (by computer) prediction and selection of product candidates, which are then advanced in its Pipeline Program. The Company's business model includes collaborations covering the further development and commercialization of product candidates at various stages from its Pipeline Program and various forms of research and discovery agreements, in both cases providing Compugen with potential milestone payments and royalties on product sales or other forms of revenue sharing. Compugen’s wholly-owned U.S. subsidiary located in South San Francisco is developing oncology and immunology monoclonal antibody therapeutic candidates against its drug targets. For additional information, please visit Compugen's corporate website at www.cgen.com.

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. These statements, include words such as “may,” “expects,” “anticipates,” “potential,” “believes,” and “intends,” and describe opinions about future events. Forward-looking statements in this press release include, but are not limited to, statements relating to the potential use of Compugen discovered checkpoint molecules as targets for antibody immunotherapy in cancer, and of CGEN-15001 as a drug candidate for the treatment of autoimmune and inflammatory diseases. These forward-looking statements involve known and unknown risks and uncertainties that may cause the actual results, performance or achievements of Compugen to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. These and other risks are discussed in the "Risk Factors" section of Compugen’s most recent Annual Report on Form 20-F as filed with the Securities and Exchange Commission as well as other documents that may be subsequently filed by Compugen from time to time with the Securities and Exchange Commission. In addition, any forward-looking statements represent Compugen’s views only as of the date of this release and should not be relied upon as representing its views as of any subsequent date. Compugen does not assume any obligation to update any forward-looking statements unless required by law.

Contacts

Compugen Ltd.
Tsipi Haitovsky
Global Media Liaison
+972-52-598-9892
tsipih@cgen.com


Source: Compugen Ltd.